PMS-DIGOXIN 0.125 MG
DIGOXIN : 0.125 MG · DIN 02245427 · PHARMASCIENCE INC
Health Canada status: CANCELLED POST MARKET
What is PMS-DIGOXIN?
PMS-DIGOXIN 0.125 MG contains DIGOXIN : 0.125 MG. It is listed in the Health Canada Drug Product Database under DIN 02245427, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 28-Oct-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-DIGOXIN used for?
Treatment of mild to moderate congestive heart failure and control of ventricular response rate in patients with chronic atrial fibrillation.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02245427 |
|---|---|
| Brand name | PMS-DIGOXIN |
| Generic / active ingredient | DIGOXIN : 0.125 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 0.125 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C01AA05 DIGOXIN |
| AHFS class | 24:04.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 28-Oct-2016 |
| Original market date | 2006-06-21 00:00:00 |
How is it administered?
Individualize based on age, body weight, and renal function. Dosage must be titrated. Bioavailability differences between forms must be considered when switching.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Standard reference is usually 15-30°C).
How is it supplied?
Not explicitly detailed in provided text (Tablets 0.0625 mg, 0.125 mg, 0.25 mg).
Contraindications
Ventricular fibrillation; hypersensitivity to digoxin or other digitalis glycosides.
Warnings and precautions
Narrow therapeutic range. Toxicity risk increased by hypokalemia, hypomagnesemia, hypercalcemia, and renal impairment. Not for obesity treatment. Use caution in acute MI.
What can be used instead?
Other Canadian products sharing ATC code C01AA05 DIGOXIN. 8 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-DIGOXIN | 0.0625 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02554399 |
| AURO-DIGOXIN | 0.125 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02554402 |
| DIGOXIN INJECTION C.S.D. | 0.5 MG / 2 ML | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02048264 |
| JAMP DIGOXIN | 0.0625 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02498502 |
| JAMP DIGOXIN | 0.125 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02498510 |
| PMS-DIGOXIN | 0.05 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02242320 |
| PMS-DIGOXIN | 0.0625 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02335700 |
| PMS-DIGOXIN | 0.125 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02335719 |
| APO-DIGOXIN | 0.0625 MG | TABLET | APOTEX INC | DORMANT | DIN 02281236 |
| APO-DIGOXIN | 0.125 MG | TABLET | APOTEX INC | DORMANT | DIN 02281228 |
Who else supplies DIGOXIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DIGOXIN appears in 52 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.